Table 1.
Baseline characteristics and risk factors in the female and male population of ischemic stroke patients.
| Variable | Overall (n = 7,300) | Women (n = 1,406, 19.3%) | Men (n = 5,894, 80.7%) | P-value |
|---|---|---|---|---|
| Age (mean, years) | 55.1 ± 13.3 | 61.6 ± 15.1 | 53.5 ± 12.3 | < 0.001 |
| Age category | ||||
| < 46 years | 1,807 (24.8) | 223 (15.9) | 1,584 (26.9) | < 0.001 |
| 46–55 years | 2,104 (28.8) | 229 (16.3) | 1,875 (31.8) | |
| 56–65 years | 1,863 (25.5) | 354 (25.2) | 1,509 (25.6) | |
| >65 years | 1,526 (20.9) | 600 (42.7) | 926 (15.7) | |
| Hypertension | 5,324 (72.9) | 1,074 (76.4) | 4,250 (72.1) | < 0.001 |
| Diabetes | 4,133 (56.6) | 880 (62.6) | 3,253 (55.2) | < 0.001 |
| Dyslipidemia | 3,500 (47.9) | 705 (50.1) | 2,795 (47.4) | 0.07 |
| Prior stroke | 872 (11.9) | 227 (16.1) | 645 (10.9) | < 0.001 |
| Atrial fibrillation on admission | 613 (8.4) | 213 (15.1) | 400 (6.8) | < 0.001 |
| Coronary artery disease | 890 (12.2) | 173 (12.3) | 717 (12.2) | 0.89 |
| Active smoking | 2,074 (28.4) | 49 (3.5) | 2,025 (34.4) | < 0.001 |
| Obesity (body mass index ≥30 kg/m2) | 1,848 (25.3) | 577 (41.0) | 1,271 (21.6) | < 0.001 |
| Prior antiplatelet use | 1,523 (20.9) | 405 (28.8) | 1,118 (19.0) | < 0.001 |
| Prior anticoagulant use | 359 (4.9) | 106 (7.5) | 253 (4.3) | < 0.001 |
| Prior anti-hypertensive use | 2,394 (32.8) | 685 (48.7) | 1,709 (29.0) | < 0.001 |
| Anti-diabetic medication use | 1,882 (25.8) | 503 (35.8) | 1,379 (23.4) | < 0.001 |
| Prior statin use | 1,629 (22.3) | 467 (33.2) | 1,162 (19.7) | < 0.001 |
| RBS on admission (mmol/L) | 9.6 ± 4.9 | 9.9 ± 5.0 | 9.5 ± 4.9 | 0.009 |
| HbA1c% | 7.5 ± 2.4 | 7.6 ± 2.4 | 7.5 ± 2.4 | 0.14 |
| Serum cholesterol (mmol/L) | 4.9 ± 1.6 | 4.8 ± 1.8 | 4.9 ± 1.5 | 0.20 |
| Serum triglyceride (mmol/L) | 1.8 ± 1.2 | 1.7 ± 1.4 | 1.8 ± 1.1 | 0.002 |
| Serum HDL (mmol/L) | 1.0 ± 0.3 | 1.2 ± 0.3 | 0.9 ± 0.3 | < 0.001 |
| Serum LDL (mmol/L) | 3.1 ± 1.1 | 2.9 ± 1.1 | 3.1 ± 1.1 | < 0.001 |
| Systolic blood pressure (mmHg) | 156.8 ± 30.4 | 152.2 ± 30.3 | 157.9 ± 30.4 | < 0.001 |
| Diastolic blood pressure (mmHg) | 90.6 ± 19.3 | 82.9 ± 18.0 | 92.4 ± 19.2 | < 0.001 |
| Body mass index on admission (kg/m2) | 27.7 ± 5.1 | 29.7 ± 6.7 | 27.2 ± 4.5 | < 0.001 |
| Antiplatelets at discharge | 6,097 (83.5) | 1,096 (78.0) | 5,001 (84.8) | < 0.001 |
| Anticoagulants at discharge | 543 (7.4) | 147 (10.5) | 396 (6.7) | < 0.001 |
| Anti-hypertensive at discharge | 4,707 (64.5) | 920 (65.4) | 3,787 (64.3) | 0.41 |
| Antidiabetics at discharge | 2,843 (38.9) | 601 (42.7) | 2,242 (38.0) | < 0.001 |
| Statin at discharge | 6,191 (84.8) | 1,141 (81.2) | 5,050 (85.7) | < 0.001 |
HDL, high-density lipoprotein; LDL, low-density lipoprotein; RBS, random blood sugar.